When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

When Biogen announced the deal, the company said it expected a “significant portion” of Apellis staffers would stay on board. (No-Mad/iStock/Getty Images Plus) Biogen isn’t wasting any time ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

The FDA has sent an End of Enforcement notice to consumer wearable device company Whoop, putting a formal end to the agency’s ...

In another sign that the FDA is easing its stance toward rare disease drug candidates under new leadership, the agency will ...

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...

With pharma heavyweights clashing against one another and reeling in major sales in the ulcerative colitis (UC) | Merck is ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts ...